



CLINICAL TRIALS OF TEXAS, INC.

Promoting Health Through Research

Curriculum Vitae

Douglas Scott Denham, DO, CPI

7940 Floyd Curl Drive, Suite 700
San Antonio, Texas 78229

7940 Floyd Curl Drive, Suite 1020
San Antonio, Texas 78229

EDUCATION

- 1989-1992 Intern/Residency, Family Practice, University of Texas at San Antonio Health Science Center, San Antonio, Texas
- 1985-1989 Doctor of Osteopathic Medicine, Texas College of Osteopathic Medicine, Forth Worth, Texas
- 1981-1983 College of William and Mary, Williamsburg, Virginia
- 1977-1981 Bachelor of Science-Biology, Hampden-Sydney College, Hampden-Sydney, Virginia

LICENSE(S)

- 1990 Drug Enforcement Administration (DEA) Controlled Substance Registration Certificate
- 1990 Texas Controlled Substance Registration Certificate
- 1990 Texas Medical Board, # H7995

CERTIFICATION(S)

- 2009 Certified Physician Investigator

PROFESSIONAL EXPERIENCE

- 2010-Present Medical Director, Clinical Trials of Texas, Inc., San Antonio, Texas
- 2008-2010 Director of Medical Affairs/Primary Investigator, Cetero Research, Inc., San Antonio, Texas
- 2006-2008 Director of Medical Affairs/Sub Investigator, Cetero Research, Inc., San Antonio, Texas
- 2002-2002 Staff Physician, NFR Medical PA, San Antonio, Texas
- 2000-Present Medical Director (PT), ABC Family Medicine, PA, San Antonio, Texas
- 2000-Present Medical Director (PT), Army Residence Community, San Antonio, Texas
- 1996-2002 Lead Physician, Quantum Windcrest Health Center, San Antonio, Texas
- 1994-1996 Lead Physician, Turtle Creek Medical Group, San Antonio, Texas
- 1994-1996 Staff Physician, Northeast Family Practice, San Antonio, Texas

PROFESSIONAL MEMBERSHIP(S)

- 1992-Present American Academy of Family Practice
- 1992-Present Texas Academy of Family Practice
- 1992-Present Texas Medical Association
- 1992-Present Bexar County Medical Society
- 1992-Present American Board of Family Practice

HOSPITAL AFFILIATION(S)

- Baptist Hospital System, San Antonio, Texas
- Methodist Hospital System, San Antonio, Texas
- Christus Santa Rosa System, San Antonio, Texas

RESEARCH EXPERIENCE

Served as Investigator on over 200 phase I-IV clinical research studies to include:

2010-Present: A Randomized, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With "Study Drug" Once Weekly In Patients With Type 2 Diabetes Mellitus (CTT-000233)

2010-Present: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three Way Crossover, Pharmacokinetic And Pharmacodynamic Study Of "Study Drug" In Patients With Claudication (CTT-000225)

2010-Present: A Randomized, Double-Blind, Placebo- And Active-Controlled Study Of "Study Drug" In The Treatment Of Neuropathic Pain In Diabetic Peripheral Neuropathy Followed By A Blinded Extension Phase (CTT-000188)

2010-Present: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three Way Crossover, Pharmacokinetic And Pharmacodynamic Study Of "Study Drug" In Patients With Claudication (CTT-000225)

2010-Present: Clinical Evaluation Of Efficacy And Safety Of "Study Drug" For Hemostasis In Subjects Undergoing Vascular Surgery (CTT-000182)

2010-Present: A Randomized-Withdrawal, Placebo-Controlled, Study Evaluating The Efficacy, Safety, And Tolerability Of "Study Drug" Extended-Release (ER) In Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN) (CTT-000208)

2010-Present: A Phase 2, Multicenter, Open-Label Study To Assess The Safety And Tolerability Of Oral "Study Drug" As Adjunctive Therapy In Adult Patients With Major Depressive Disorder (CTT-000228)

2010-Present: A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Trial Of "Study Drug" Administered Orally Once Daily In Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder In The United States (CTT-000196)

2010-Present: Evaluation Of "Study Drug" In Combination With L-Carnitine In Subjects With Intermittent Claudication (CTT-000193)

2010-Present: A Phase 2, Gender-Stratified, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Immunogenicity Of A Two Vaccination Regimen With The Travelers' Diarrhea Vaccine System In Healthy Adults (CTT-000214)

2010-Present: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of "Study Drug" As Adjunctive Therapy In The Treatment Of Adults With Major Depressive Disorder (CTT-000217)

2010-Present: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Of "Study Drug" In Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (CTT-000216)

2010-Present: A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of "Study Drug" When Used In Combination With "Study Drug" Compared With "Study Drug" Plus "Study Drug", "Study Drug" Plus "Study Drug", And "Study Drug" Plus Placebo In Subjects With Type 2 Diabetes Mellitus (CTT-000168)

2010-Present: A Randomized, Open-Label, Parallel-Group, Multicenter Study To Determine The Efficacy And Long Term Safety Of "Study Drug" Compared With Insulin In Subjects With Type 2 Diabetes Mellitus (CTT-000169)

2010-Present: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of "Study Drug" When Used In Combination With "Study Drug" With Or Without "Study Drug" In Subjects With Type 2 Diabetes Mellitus (CTT-000170)

2010-Present: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of Two Dose Levels Of "Study Drug" Compared With Placebo In Subjects With Type 2 Diabetes Mellitus (CTT-000171)

2010-2010: A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of "Study Drug" Administered In Combination With "Study Drug" And "Study Drug" Compared With "Study Drug" Plus "Study Drug" And Placebo And With "Study Drug" Plus "Study Drug" And "Study Drug" In Subjects With Type 2 Diabetes Mellitus (CTT-000172)

2010-2010: A One-Year, Randomized, Open-Label, Parallel-Group, Multiple-Dose Long-Term Safety Study With Controlled Adjustment Of Dose Of "Study Drug" And "Study Drug" In Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN) (CTT-000222)

Previous Experience

A Phase I, Randomized, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of "Study Drug" In Subjects With Type 2 Diabetes

A Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Ascending Oral Doses Of "Study Drug" In Subjects With Type 2 Diabetes Mellitus

A Double-Blind, Randomized, Placebo- And Active-Controlled, Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of "Study Drug" In Subjects With Type 2 Diabetes Mellitus

A Phase IIA, Double-Blind, Randomized, Parallel-Group, Multi-Centre Study To Evaluate The Analgesic Efficacy Of 28 Days' Oral Administration Of "Study Drug" Compared With Placebo In Patients With Painful Diabetic Neuropathy

A Phase 2A, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate The Safety And Efficacy Of "Study Drug" On Reducing Albuminuria In Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With An Renin-Angiotensin System Inhibitor

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Examine The Safety, Tolerability, And Effect On Body Weight Of "Study Drug" Administered In Conjunction With "Study Drug" In Obese And Overweight Subjects

A Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing The Efficacy And Safety Of "Study Drug" With Placebo In The Management Of Pain Associated With Painful Diabetic Neuropathy

A Phase III Open-Label Titration Trial To Evaluate The Effectiveness And Safety Of Different Doses Of A Dermal Application Of "Study Drug" In Hypogonadal Men

A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Safety And Efficacy Of "Study Drug" In Overweight And Obese Patients

A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Safety And Efficacy Of "Study Drug" In Overweight And Obese Patients With Type 2 Diabetes Mellitus Managed With Oral Hypoglycemic Agent(s)

A Randomized, Open-Label, Parallel-Group, Comparator-Controlled, Multicenter Study To Evaluate The Glycemic Effects, Safety, And Tolerability Of "Study Drug" Once Weekly In Subjects With Type 2 Diabetes Mellitus

An Open-Label Study Of The Efficacy And Safety Of "Study Drug" In The Treatment Of The Signs And Symptoms Of Endogenous Cushing's Syndrome

A Study To Confirm The Presence Of Recurrent Or Persistent Cushing's Syndrome In Patients With Clinical Signs Or Symptoms Of Hypercortisolemia Who Have Been Treated For Cushing's Disease

A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Subcutaneous Doses Of "Study Drug" In Type 2 Diabetic Adult Subjects

A Randomized, Single Site, Open-Label, 4-5 Way Crossover Meal Challenge Study Comparing Time Action Profiles Of "Study Drug" vs. "Study Drug," Both In Combination With "Study Drug" In Male And Female Subjects With Type 1 Diabetes Mellitus

A Phase I, Randomized, Dose-Ranging, Pharmacokinetic, Glucodynamic, Safety, And Tolerability Study Of Subcutaneously Administered "Study Drug" And "Study Drug" With Or Without Recombinant Human Hyaluronidase (rHuPH20) In Healthy Volunteers

A Randomized, Double-Blind, Placebo-And Active Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of "Study Drug" When Used In Combination With Metformin Compared With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, And Metformin Plus Placebo In Subjects With Type 2 Diabetes Mellitus "Study" In Accordance With Sponsor's Protocol No. "Protocol"

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of Two Dose Levels Of "Study Drug" Compared With Placebo In Subjects With Type 2 Diabetes Mellitus In Accordance With Sponsor's Protocol No. "Protocol"

A Randomized, Double-Blind, Placebo-And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of "Study Drug" Administered In Combination With Metformin And Glimepiride Compared With Metformin Plus Glimepiride And Placebo And With Metformin Plus Glimepiride, And Pioglitazone In Subjects With Type 2 Diabetes Mellitus

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Safety And Tolerability Of "Study Drug" Compared To Placebo In Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial To Evaluate The Safety And Efficacy Of "Study Drug" In Combination With Thiazolidinedione Therapy In Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control On Thiazolidinedione Therapy Alone

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy And Safety Study Of "Study Drug," Administered Orally Once Daily For 18 Weeks Followed By A 34 Week Double-Blind Extension Period (Placebo Patients Switched To "Study Drug") In Type 2 Diabetic With Insufficient Glycemic Control For Whom Metformin Therapy Is Inappropriate (Intolerability Or Contraindication)

A Phase II, Double Blind, Randomized, Placebo-Controlled Study Of The Safety, Tolerance And Activity Of "Study Drug" When Administered Orally For 12 Weeks To Adult Patients With Type 2 Diabetes Mellitus Effects Of "Study Drug" On Reverse Cholesterol Transport And Kinetic Parameters In Normal Subjects, And Subjects With Low HDL-C Levels

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of "Study Drug" With 28 Days Of Subcutaneous Injections In Subjects With Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Of "Study Drug" In Patients With Type 2 Diabetes Mellitus

A Proof Of Concept Study To Evaluate The Co-Administration Of "Study Drug" Given Daily And "Study Drug" Given Once-Weekly For Four Weeks In Patients With Type 2 Diabetes Mellitus

A Randomized Trial Comparing "Study Drug" With Placebo In Subjects With Type 2 Diabetes On Insulin Glargine With Or Without Oral Antihyperglycemic Medications

A Phase 2/3, Placebo-Controlled, Efficacy And Safety Study Of Once-Weekly, Subcutaneous “Study Drug” Compared To Sitagliptin In Patients With Type 2 Diabetes Mellitus On Metformin

Efficacy Of Once-Weekly “Study Drug” And Once-Daily “Study Drug” In Patients With Type 2 Diabetes Treated With Metformin Alone Or In Combination With Sulfonylurea

The “Study Device” For The Treatment Of Type 2 Diabetes: A Randomization Study

A Prospective, Clinical Trial Of The “Study Device” In Treatment Of Obese To Morbidly Obese Patients

A Multinational, Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, 2 x 2 Factorial Design Study Of The Efficacy And Safety Of Long Term Administration Of “Study Drug” And Valsartan In The Prevention Of Diabetes And Cardiovascular Outcomes In Subjects With Impaired Glucose Tolerance (IGT)

A Multi-Center, Randomized, Double Blind Study To Evaluate The Efficacy And Long-Term Safety Of “Study Drug” As Monotherapy In Patients With Type 2 Diabetes

An 8-Week Randomized, Double-Blind, Parallel-Group, Multicenter, Active Controlled Dose Escalation Study To Evaluate The Efficacy And Safety Of “Study Drug” Compared To Amlodipine (10mg) In Patients W/ Stage 2 Systolic Hypertension And Diabetes Mellitus

A Phase 2 Multicenter, Randomized, Double Blind, Placebo And Active Comparator-Controlled Study To Evaluate The Safety And Efficacy Of “Study Drug” In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control On Metformin Monotherapy

A Multi-Center, Randomized, Open-Label, Cross-Over Study To Explore Effectiveness, Safety And Preference Of A New Disposable Pen “Study Device” vs. Flexpen In Subjects With Type 1 Or Type 2 Diabetes

“Study Drug” Effect On Glycemic Control Of Two Doses Of “Study Drug” Versus Glimepride In Type 2 Diabetes: A Fifty-Two Week(With 52 Week Open-Label Extension), Semi-Blind, Multicenter, Randomized, Parallel Study To Investigate Safety And Efficacy

A 24 Week, Double-Blind, Placebo-Controlled, Multi-Site Study Of “Study Drug” In Subjects With Type 2 Diabetic Neuropathy In Which The Following Are Evaluated: 1. Quantitative Sensation In Feet Measuring Vibration Perception Threshold, 2. Neuropathic Symptoms, 3. Homocysteine, Methyl Malonic Acid And Vitamin B Plasma Levels, And 4. Quality Of Life

A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi-Center Study To Evaluate Safety And Efficacy Of “Study Drug” As Monotherapy In Subjects With Type 2 Diabetes Mellitus

An Open Label, Multi-Center, Long-Term Follow-Up Study To Evaluate The Safety Of “Study Drug” In Subjects With Type 2 Diabetes Mellitus

A 52-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Phase IIB Trial To Determine The Effects Of “Study Drug” On eGFR In Patients With Type 2 Diabetes And Chronic Kidney Disease With An eGFR Of 20-45

Effect Of “Study Drug” Treatment On Glycemic Control In Patients With Type 2 Diabetes Mellitus And Obstructive Sleep Apnea

Long-Term Follow-Up Of Subjects Treated With Or Exposed To “Study Drug” Plasmid Gene Therapy

A Phase 2 Repeat Dosing Clinical Trial Of “Study Drug” In Subjects With Moderate To Severe Diabetic Neuropathy And Unmeasurable Nerve Conduction Velocity

A Prospective, Open-Label, Ambulatory Blood Pressure Monitoring (ABPM) Dose Titration Study To Evaluate The Safety And Efficacy Of An “Study Drug” And “Study Drug” Based Treatment Regimen In Hypertensive, Type 2 Diabetic Subjects

Long-Term Follow-Up Of Subjects With Diabetic Neuropathy Previously Treated With “Study Drug”

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of “Study Drug” As Monotherapy For Type 2 Diabetes Mellitus

A Phase 2 Study Of Stem-Cell-Mobilization In Subjects With Diabetic Neuropathy Receiving “Study Drug”

A Multicenter, Randomized, Placebo-Controlled, "Factorial" Design, 12-Month Study To Evaluate The Efficacy Of “Study Drug” Co-Administered With All Registered Atorvastatin Strengths Ranging From 10 mg To 80 mg In Patients With Primary Hypercholesterolemia

A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel-Group, Multicenter Study With A 24-Week Main Treatment Period And An Extension Assessing The Efficacy And Safety Of “Study Drug” In Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin

A Randomized, Placebo-Controlled, Parallel Design Study To Evaluate The Effect Of “Study Drug” On LDL-C And Other Plasma Lipoproteins In Dyslipidemic Patients

Effects Of “Study Drug” On Glycemic Control And Safety Of “Study Drug” Over One Year In Subjects With Type 2 Diabetes Under Diet Control And Exercise

TRX4 Therapeutic Evaluation Of Different Multi-Dose Regimens In Type 1 Diabetes

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study Of “Study Drug” In Patients With Type 2 Diabetes Treated With Metformin And/Or TZD

A Long-Term, Open-Label Extension Study To Investigate the Long-Term Safety Of “Study Drug” In Subjects With Type 2 Diabetes

A Multicenter, Randomized, Double-Blind Study To Determine The Efficacy And Safety Of The Addition Of “Study Drug” Versus Dose Titration From 30 MG To 45 MG Of “Study Drug” In Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Control On A Combination Of Metformin And 30 MG Of Pioglitazone HCl Therapy

A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of “Study Drug” Administered In Combination With Metformin And Glimepiride Compared With Metformin Plus Glimepiride And Placebo And With Metformin Plus Glimepiride And Proglitazone In Subjects With Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of “Study Drug” When Used In Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, And Metformin Plus Placebo In Subjects With Type 2 Diabetes Mellitus

A Long-Term, Open-Label Extension Study To Investigate The Long-Term Safety Of “Study Drug” In Subjects With Type 2 Diabetes

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of Two Dose Levels Of “Study Drug” Compared With Placebo In Subjects With Type 2 Diabetes Mellitus

Other relevant research experience:
COPD in diabetic patients

Signature and Date